0001209191-20-057783.txt : 20201110
0001209191-20-057783.hdr.sgml : 20201110
20201110192809
ACCESSION NUMBER: 0001209191-20-057783
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201109
FILED AS OF DATE: 20201110
DATE AS OF CHANGE: 20201110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stamm Luisa M
CENTRAL INDEX KEY: 0001793158
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35005
FILM NUMBER: 201302598
MAIL ADDRESS:
STREET 1: C/O ASSEMBLY BIOSCIENCES, INC.
STREET 2: 11711 N. MERIDIAN ST, SUITE 310
CITY: CARMEL
STATE: IN
ZIP: 46032
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0001426800
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 331 OYSTER POINT BLVD.
STREET 2: FOURTH FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (833) 409-4583
MAIL ADDRESS:
STREET 1: 331 OYSTER POINT BLVD.
STREET 2: FOURTH FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC
DATE OF NAME CHANGE: 20080211
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-09
0
0001426800
ASSEMBLY BIOSCIENCES, INC.
ASMB
0001793158
Stamm Luisa M
C/O ASSEMBLY BIOSCIENCES, INC.
331 OYSTER POINT BLVD., FOURTH FLOOR
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Common Stock
2020-11-09
4
S
0
4397
5.0952
D
7603
D
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.13, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.
/s/ John O. Gunderson, as Attorney-in-Fact
2020-11-10